About Pinnacle Biologics
Pinnacle Biologics is a Healthcare company based in Chicago (United States) founded in 2007, and was acquired by Advanz Pharmaceutical in December 2013. Photodynamic therapies for cancers and rare diseases are developed. Pinnacle Biologics has raised $1.5 million across 1 funding round from investors including Advanz Pharmaceutical. The company has 12 employees. Pinnacle Biologics offers products and services including Specialty Therapies. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Pinnacle Biologics, Inc.
Company details
Pinnacle Biologics develops therapies to treat various cancers and rare diseases. Pinnacles on-market products include Photofrin, a photosensitizer used in photodynamic therapy (PDT) of tumors. Photofrin is FDA approved for multiple indications including the treatment of non-small cell lung cancer (NSCLC) and esophageal cancer. It also is approved for high-grade dysplasia (HGD) in Barretts esophagus (BE) in North America. The company is also investigating Photofrin in patients with brain cancer. As of Dec 2013, Pinnacle Biologics operates as a subsidiary of Concordia Healthcare Corp.
- Headquarters Chicago, United States
- Employees 12
- Stage Acquired
- SectorsHealthcare
- Website pinnaclebiologics.com
- Social LinkedIn
- Acquired by Advanz Pharmaceutical (Dec 2013)
- Legal Name Pinnacle Biologics, Inc.
- Total Equity Funding$1.5M (USD)
in 1 rounds
- Latest Funding Round$1.5M (USD), Seed
Dec 2011
- Investors
- Employee Count12
- Acquired byAdvanz Pharmaceutical
(Dec 2013)
Products & Services of Pinnacle Biologics
Pinnacle Biologics offers a comprehensive portfolio of products and services, including Specialty Therapies.
Enables critical therapies to maximize potential for patient care
Funding Insights of Pinnacle Biologics
Pinnacle Biologics has successfully raised a total of $1.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.5 million completed in December 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.5M
- Total Rounds 1
- Last Round Seed — $1.5M
- First Round $1.5M
(Dec 2011)
All 1 funding rounds of Pinnacle Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2011 | $1.5M | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Pinnacle Biologics
Pinnacle Biologics has secured backing from 1 investor. Prominent investors backing the company include Advanz Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Specialty generic and off-patent medicines are manufactured in various forms. | 1963 | advanzpharma.com | Mississauga, Canada |
Investor details for Pinnacle Biologics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pinnacle Biologics
1 people are tracked at Pinnacle Biologics (1 in leadership); the tracked headcount is 12.
| Name | Role | Group |
|---|---|---|
Larry Miles | President | Leadership |
Complete people profiles for Pinnacle Biologics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pinnacle Biologics
3 dated milestones of Pinnacle Biologics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Pinnacle Biologics is founded.
- Funding First funding round of $1.5M.
- Exit Acquired by Advanz Pharmaceutical.
Top companies in Oncology
3 companies that operate in the same segment as Pinnacle Biologics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pinnacle Biologics
Complete news archive for Pinnacle Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pinnacle Biologics
Pinnacle Biologics was founded in 2007 and raised its 1st funding round 4 years after it was founded.
Pinnacle Biologics is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Pinnacle Biologics is a funded company, having raised a total of $1.5M across 1 funding round to date. The company's 1st funding round was a Seed of $1.5M, raised on Dec 2011.
Pinnacle Biologics has 12 employees.
Pinnacle Biologics develops therapies to treat various cancers and rare diseases. Pinnacles on-market products include Photofrin, a photosensitizer used in photodynamic therapy (PDT) of tumors. Photofrin is FDA approved for multiple indications including the treatment of non-small cell lung cancer (NSCLC) and esophageal cancer. It also is approved for high-grade dysplasia (HGD) in Barretts esophagus (BE) in North America. The company is also investigating Photofrin in patients with brain cancer. As of Dec 2013, Pinnacle Biologics operates as a subsidiary of Concordia Healthcare Corp.
Pinnacle Biologics offers Specialty Therapies.
Pinnacle Biologics has 1 investor. Key investors include Advanz Pharmaceutical.
Pinnacle Biologics operates through Pinnacle Biologics, Inc..
Yes. Pinnacle Biologics was acquired by Advanz Pharmaceutical in December 2013.